Pharmafile Logo

In-person, hybrid, or digital? State of Pharma meetings and events in 2024

March 18, 2024 |  

We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

- PMLiVE

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.

Why in-person-only should be a thing of the past

I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:

  • Expensive
  • Associated with a large environmental footprint
  • Inflexible and not accommodating to everyone’s schedules, work or personal commitments, and preferences
  • Susceptible to last-minute no-shows due to flight delays or poor driving conditions

Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:

  • Valuable time wasted on didactic data presentations
  • Very limited “air time” per participant
  • Uneven share of voice, with more extroverted or senior advisors tending to take up more speaking time
  • A tendency for answers to be “knee-jerk reactions” rather than thought-through responses and for people to simply ‘agree’ with others
  • Limited ability to dive deeper into interesting or controversial ideas
  • Suboptimal diversity of advisors due to potential geographic or language barriers

Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…

[Read the full article here]

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Leveraging Real-Time Health Data for Proactive, Predictive Care

Alex Gilbert, Head of Digital Medicines Development & Life Sciences Partnerships at Huma, explores virtual & decentralized trials, digital biomarkers, digital-first delivery of care, at-home hospitals, and many other thought-provoking...

Top 10 Tips for “Virtualizing” In-person Meetings

While Pharma was already slowly pivoting towards virtual events as a substitute for, or supplement to, in-person meetings, COVID-19 quickly changed virtual events from a nice-to-have to a must. With...

Virtualizing Healthcare with Human-Centric Technology

Dr. Patrick Carroll, Chief Medical Officer at Vida Health, discusses the importance of using a “whole health” approach to chronic disease management, how and why the human connection with a...

Importance of Diversity in Pharma and Clinical Trials

No matter which sector you work in, diversity and inclusion are must-haves!

Case Study: Reducing Travel-Related Emissions and Costs Through Virtual Events

In early 2021, due to COVID-19-related safety concerns and travel and social distancing restrictions, our client needed help to “virtualize” their nationwide, multi-day, multi-business unit internal event with 375 attendees....

Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal

A version of this article was previously published on Pharmaphorum.There is not a single industry that has been left untouched by COVID-19. While the effects of the pandemic have been devastating...

Data-Driven Approaches for Neurorecovery

Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine...

Online Advisory Boards: Top 10 Frequently Asked Questions

It’s hard to imagine a time when some people in the life science industry had never attended a web meeting. Yet, that’s the reality we were living in just two...

Top 10 Tips for Creating Company Culture in a Virtual World

For many companies, the transition from in-office to remote or flexible work at the beginning of the pandemic may have started off a bit rocky. However, a recent survey from LinkedIn...

Democratizing Brain Health with Digital Assessments

Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can...